Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 74 of 116

  1. Tecentriq 1 200 mg concentrate for solution for infusion

    Wuhan Createrna Science and Technology Co., Ltd

    Limited disease small-cell lung cancer

    phase 2 small molecule active

    1 trial

  2. Tecentriq 1 200 mg concentrate for solution for infusion

    Tour Hekla

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  3. Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Locally advanced cervical cancer

    phase 2 small molecule active

    1 trial

  4. Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    (Diffuse) Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  5. Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  6. Tegafur Gimeracil Oteracil Potassium Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Telehealth Intervention

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 2 other active

    1 trial

  8. Telisotuzumab Vedotin

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  10. Temsirolimus

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  11. Teniposide administration

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  12. Tepotinib

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  13. Tepotinib

    Serono Europe Limited

    Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification

    phase 2 small molecule active

    1 trial

  14. Testosterone Enanthate 100 MG/ML Injectable Solution

    Hospital Authority, Hong Kong

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  15. Testosterone cypionate

    United Therapeutics Europe Ltd

    Castration Resistant Metastatic Prostate Cancer

    phase 2 small molecule completed

    1 trial

  16. Teverelix TFA

    Nordic Bioscience A/S

    Advanced prostate cancer

    phase 2 small molecule active

    1 trial

  17. Tevimbra 100 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.

    phase 2 small molecule active

    1 trial

  18. Thalidomide and methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-LGL Leukemia

    phase 2 small molecule active

    1 trial

  19. Tipifarnib

    Kura Oncology

    Thyroid Cancer

    phase 2 small molecule completed

    1 trial

  20. Tipifarnib

    Kura Oncology

    Relapsed or Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  21. Tipifarnib

    Kura Oncology

    Leukemia, Myelomonocytic, Chronic

    phase 2 small molecule completed

    1 trial

  22. Tiragolumab

    Hoffmann-La Roche

    Cervical Cancer

    phase 2 small molecule completed

    1 trial

  23. Tiragolumab for HNSCC, metastatic deficient mis…

    Disc Medicine

    HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor

    phase 2 small molecule active

    1 trial

  24. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  25. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  26. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  27. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    RECTAL NEOPLASMS

    phase 2 small molecule active

    1 trial

  28. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Advanced Unresectable Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  29. Tislelizumab

    The First People's Hospital of Lianyungang

    Bladder Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  30. Tislelizumab

    The First People's Hospital of Lianyungang

    Biliary Tract Tumor

    phase 2 small molecule active

    1 trial

  31. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  32. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  33. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Thyroid Cancer

    phase 2 small molecule active

    1 trial

  34. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Resectable Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  35. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  36. Tislelizumab

    The First People's Hospital of Lianyungang

    HER2-positive or Mutated Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  37. Tislelizumab

    The First People's Hospital of Lianyungang

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  38. Tislelizumab

    BeiGene

    Cervical Cancer

    phase 2 mab completed

    1 trial

  39. Tislelizumab

    Hospital Authority, Hong Kong

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  40. Tislelizumab (BGB-A317)

    BEONE MEDICINES AUS PTY LTD

    MSI-H/dMMR Solid Tumors

    phase 2 small molecule active

    1 trial

  41. Tislelizumab combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  42. TmBU conditioning Regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  43. Tolecizumab (PCSK9 Inhibitor)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colon Adenocarcinoma

    phase 2 small molecule active

    1 trial

  44. Tolinapant, Tolinapant

    Taiho Pharma Netherlands B.V.

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    phase 2 small molecule active

    1 trial

  45. Toripalimab

    The First People's Hospital of Lianyungang

    Adenocarcinoma of the Stomach

    phase 2 small molecule active

    1 trial

  46. Toripalimab

    The First People's Hospital of Lianyungang

    Urinary Bladder Neoplasms

    phase 2 small molecule active

    1 trial

  47. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Triple-Negative Breast Cancer (TNBC)

    phase 2 small molecule active

    1 trial

  48. Toripalimab

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.